Also found in: Medical.
ABECBacute bacterial exacerbations of chronic bronchitis
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The warnings and precautions section of the fluoroquinolone labels are also being updated and will include "new limitation-of-use statements to reserve fluoroquinolones for patients who do not have other available treatment options for ABS, ABECB, and uncomplicated UTIs," the FDA statement said.
(23) A recent study by Kahn et al evaluated patients with ABECB. These 3 pathogens were found in 46.2% (147/318) of patients with less severe symptoms and 41.9% (143/341) of patients with more severe symptoms.
(6,2) More alarmingly, in a recent clinical study of younger, low-risk patients with ABECB, 35% of S.
In ABECB, variables associated with treatment failure may be loosely categorized as those relating to clinical issues (eg, infection with a resistant pathogen) or those resulting in increased costs.
The safety and efficacy of short-course (3-5 day), 750 mg levofloxacin (LVX) for acute bacterial exacerbation of chronic bronchitis (ABECB).
The antimicrobial treatment recommendations reported in this article and summarized in TABLE 2 are taken from guidelines developed by consensus committees of physicians convened by professional organizations interested in the study and treatment of ABS, ABECB, and CAP.
RELATED ARTICLE: Table 1: Criteria for Optimized Therapy of ABECB (6)
* Recommended Dosage: 400 mg orally once a day for 5 days (for ABECB) or 10 days (for CAP and sinusitis).
* Antibiotic therapy for community-acquired bacterial RTIs, including acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (ABECB), and community-acquired pneumonia (CAP), is typically empiric and requires careful evaluation of patients and antibiotics.
The findings suggest that macrolide antibiotics remain a viable option for treatment of ABECB, the investigators said.
A fluoroquinolone for ABECB, acute sinusitis, CAP, uncomplicated and complicated urinary tract infections, pyelonephritis, uncomplicated urethral and cervical gonorrhea; also for acute uncomplicated rectal infections in women due to Neisseria gonorrhoeae.
The safety and efficacy of short-course (3-5 days), 7500 mg levofloxacin (LVX) for acute bacterial exacerbation of chronic bronchitis (ABECB).